Pfizer-BioNTech is reporting positive results in its testing of the COVID-19 vaccine in kids between the ages of 12 and 15.
A recent preliminary study of over 22 hundred youth, found the shots had 100 per cent effectiveness and were well tolerated.
The companies plan to submit this new data to the U.S. Food and Drug Administration and the European Medicines Agency as soon as possible.
It says the study will continue to track participants for two years.
Studies are also underway for children aged 6 months to 11 years.
Today, with @BioNTech_Group, we announced positive topline results in adolescents 12-15 years of age from the Phase 3 Pfizer-BioNTech #COVID19 vaccine study.
— Pfizer Inc. (@pfizer) March 31, 2021
